CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Consent and Termination AgreementConsent and Termination Agreement • May 2nd, 2024 • Blueprint Medicines Corp • Pharmaceutical preparations
This Consent and Termination Agreement (this “Termination Agreement”), dated February 22, 2024, is by and between Royalty Pharma Investments 2019 ICAV, an Irish collective-asset management vehicle (“Investor”), and Blueprint Medicines Corporation (“Company”). Reference is made to that certain Purchase and Sale Agreement, dated June 30, 2022, by and between Investor and Company (the “RPA”). Any capitalized term used but not defined in this Termination Agreement shall have the meaning ascribed to such term in the RPA.
